SinoMab BioScience Limited — Director's Dealing 2021

Dec 23, 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [29 x 44] intentionally omitted <==

==> picture [29 x 44] intentionally omitted <==

SinoMab BioScience Limited 中國抗體製藥有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 3681)

GRANT OF RESTRICTED SHARE UNITS

Reference is made to the prospectus dated 31 October 2019 of SinoMab BioScience Limited (中國 抗 體製 藥 有限 公司 ) (the ‘‘Company’’, together with its subsidiaries, the ‘‘Group’’) in relation to the Company’s restricted share unit scheme (the ‘‘RSU Scheme’’).

The board of directors (the ‘‘Board’’) of the Company hereby announces that, on 14 December 2021, the Company has resolved to make a grant of restricted share units under the RSU Scheme conditionally adopted on 18 October 2019 with effect from 12 November 2019. The RSU Scheme aims to incentivise the directors, senior management and employees of the Group for their contribution to the Group and to attract, motivate and retain skilled and experienced personnel to strive for the future development and expansion of the Group, by providing them with the opportunity to own equity interests in the Company. Shares representing the maximum overall limit of ordinary shares of the Company (being 36,174,400 ordinary shares of the Company) pursuant to the RSU Scheme were allotted and issued to Skytech Technology Limited before the listing of the Company for the purpose of establishing the RSU Scheme and are currently held by Computershare Hong Kong Nominees Limited (‘‘Computershare’’) for the beneficiaries of the RSU Scheme.

On 14 December 2021, the Company granted 26,111,996 restricted share units (the ‘‘RSUs’’) under the RSU Scheme in respect of a total of 26,111,996 ordinary shares of the Company to Mr. Jing QIANG (the ‘‘Grantee’’) (the ‘‘Grant’’), representing approximately 2.595% of the total issued share capital of the Company as at the date of this announcement. On the same date as the Grant, the RSUs were vested in the Grantee and Computershare transferred 26,111,996 ordinary shares of the Company to the Grantee.

– 1 –

No new ordinary share of the Company has been issued by the Company as a result of the Grant and therefore, there is no dilution effect on the existing shareholders of the Company. The closing price of the ordinary shares of the Company on the date of the Grant was HK$2.9.

As at the date of the Grant, the Grantee was a Director and the Grant formed part of his remuneration under his service contract, and was fully exempt from the reporting, announcement and independent shareholders’ approval requirements under Rules 14A.73(6) and 14A.95 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By Order of the Board SinoMab BioScience Limited Dr. Shui On LEUNG Executive Director, Chairman and Chief Executive Officer

Hong Kong, 23 December 2021

As at the date of this announcement, the executive Director is Dr. Shui On LEUNG, the non-executive Directors are Dr. Haigang CHEN, Mr. Xun DONG, Mr. Senlin LIU, Ms. Wenyi LIU, Ms. Jie LIU and Mr. Lei SHI, and the independent non-executive Directors are Mr. George William Hunter CAUTHERLEY, Mr. Ping Cho Terence HON, Dr. Chi Ming LEE and Mr. Dylan Carlo TINKER.

– 2 –